[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cyclophosphamide-reduced-dose\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cyclophosphamide-reduced-dose":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100569553","phase-2-reduced-dose-of-cyclophosphamide-combined-with-standard-immunosuppressive-therapy-to-treat-severe-aplastic-anemia-100569553",false,"NCT06695741","Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia","Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy as Front-line Therapy in Patients With Severe Aplastic Anemia","hypo-CASH","Inclusion Criteria:\n\n* Subject has a diagnosis of naïve severe or very severe aplastic anemia\n* Male or female age ≥ 12 years\n* Unwilling or unable to receive allogeneic hematopoietic stem cell transplantation.\n* ECOG performance status ≤2\n* Willing and able to comply with the requirements for this study and written informed consent.\n\nExclusion Criteria:\n\n* Previously received immunosuppressive therapy \\> 4 weeks\n* Previously treated with TPO-RA \\> 4 weeks\n* Have an allergy or intolerance to anti-lymphocyte globulin, cyclosporine, herombopag or cyclophosphamide.\n* Uncontrolled fungal, bacterial, or viral infection. Hepatitis-associated aplastic anemia is allowed; hepatitis B or C infection is permitted unless it causes severe liver failure.\n* Tested positive for HIV or syphilis\n* Presence of severe liver, kidney, or heart failure, or other life-threatening comorbidities.\n* History of radiotherapy and chemotherapy for malignant solid tumors in recent 5 years\n* Combined with other serious disorders\n* Pregnant or breast-feeding patients\n* Patients considered to be ineligible for the study by the investigator for reasons other than the above.","ALL","12 Years",{"count":20,"type":21},75,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a prospective, single-center, single-arm, phase 2 study. This study aims to evaluate the efficacy and safety of anti-lymphocyte globulin plus herombopag in combination with the reduced dose of cyclophosphamide (hypo-CASH) for severe aplastic anemia.",[27,28,29],"Severe Aplastic Anemia","Cyclophosphamide Reduced-dose","Immunosuppressive Therapy","RECRUITING","2024-11-16",{"date":33,"type":34},"2024-11-19","ACTUAL",{"date":36,"type":34},"2024-11-01",{"date":38,"type":21},"2027-06-30",{"name":40,"class":41},"Institute of Hematology & Blood Diseases Hospital, China","OTHER"]